Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2013 - 2019)
Ultragenyx Pharmaceutical (RARE) reported Current Deferred Revenue of $69000.0 for Q1 2019, down 90.46% year-over-year from $723000.0 in Q1 2018, and down 94.45% on a QoQ basis from $1.2 million in Q2 2018.
Ultragenyx Pharmaceutical (RARE) has 7 years of Current Deferred Revenue data on file, last reported at $69000.0 in Q1 2019.
- Quarterly Current Deferred Revenue fell 90.46% year-over-year to $69000.0 in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $69000.0 (down 90.46% YoY) and the FY2017 annual result came in at $6.0 million, up 1655.43% from the prior year.
- Current Deferred Revenue fell to $69000.0 in Q1 2019 per RARE's latest filing, from $1.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $6.0 million in Q4 2017 and bottomed at $69000.0 in Q1 2019.
- The 5-year median for Current Deferred Revenue is $328000.0 (2016), against an average of $794000.0.
- The widest annual swing landed in 2017, when Current Deferred Revenue jumped 1655.43%; it then sank 90.46% in 2019.
- Tracing RARE's Current Deferred Revenue over 5 years: stood at $192000.0 in 2015, then surged by 77.6% to $341000.0 in 2016, then jumped by 1655.43% to $6.0 million in 2017, then slumped by 79.22% to $1.2 million in 2018, then plunged by 94.45% to $69000.0 in 2019.
- Per Business Quant, the three latest RARE Current Deferred Revenue figures stand at $69000.0 (Q1 2019), $1.2 million (Q2 2018), and $723000.0 (Q1 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 69,000.00 |
| Jun 30, 2018 | 1.24 Mn |
| Mar 31, 2018 | 723,000.00 |
| Dec 31, 2017 | 5.99 Mn |
| Sep 30, 2017 | 695,000.00 |
| Jun 30, 2017 | 669,000.00 |
| Mar 31, 2017 | 637,000.00 |
| Dec 31, 2016 | 341,000.00 |
| Sep 30, 2016 | 328,000.00 |
| Jun 30, 2016 | 315,000.00 |
| Mar 31, 2016 | 303,000.00 |
| Dec 31, 2015 | 192,000.00 |
| Sep 30, 2015 | 163,000.00 |
| Jun 30, 2015 | 155,000.00 |
| Mar 31, 2015 | 90,000.00 |
| Dec 31, 2014 | 85,000.00 |
| Sep 30, 2014 | 80,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Mar 31, 2014 | 78,000.00 |
| Dec 31, 2013 | 78,000.00 |